Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

HIV & AIDS Health Center

Font Size

Adding New Drugs Keeps HIV Down


In this new study, Albrecht, a researcher at Harvard's Beth Israel Deaconess Medical Center, and co-workers studied 195 people with HIV. All of them had been treated only with nucs, such as AZT, Videx, and Hivid. Most had taken at least two of these drugs for a long time. Though they were doing pretty well most had low -- but not dangerously low -- numbers of immune system cells needed to fight HIV, and HIV levels were rising.

For the new HIV cocktail, the researchers gave all the study participants two nucs -- at least one of which was new to them. They also gave them one of three other HIV treatments: the non-nuc Sustiva, the PI Viracept, or a combination of the two.

After 48 weeks of treatment, those who took the four-drug cocktail had much lower levels of HIV in their blood. The four drugs worked and kept on working for 77% of the patients. Interestingly, just adding Sustiva to the old drug regimen worked longer than adding only Viracept.

"Even in patients who have been maintained for a long time on dual or triple nucleoside therapy, [treatment] can be enhanced by addition of two new classes of drug," Albrecht says.

The study raises many questions. In the U.S. and Europe, almost nobody starts treatment with just nucs any more. If two new classes of drug are needed for effective salvage therapy, what should a patient start with? Is it better to use an all-out approach at first to keep the virus in check? Or is it better to use only two classes at first and save the other two for later? And will new drugs really be there when they are needed?

Mellors says that the answers to these questions rely more on the art than on the science of medicine.

"When the patient is relatively stable and there is no-near term risk of AIDS or death, then we can wait until we have several drugs available -- each from a new class -- to put in a multidrug combination," Mellors says.

Today on WebMD

How much do you know?
contemplative man
What to do now.
Should you be tested?
HIV under microscope
What does it mean?
HIV AIDS Screening
man opening condom wrapper
HIV AIDS Treatment
Discrimination Stigma
Treatment Side Effects
grilled chicken and vegetables
obese man standing on scale
cold sore